Advertisement

Topics

Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth

08:03 EDT 3 Aug 2017 | FinanzNachrichten

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) reported Thursday that its second-quarter net income climbed 98% to $388 million from prior year's $196 million. Earnings per share gre...

Original Article: Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth

NEXT ARTICLE

More From BioPortfolio on "Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth"

Quick Search
Advertisement